A Prospective Phase I and II Trial of Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 30 Jan 2019
At a glance
- Drugs Abemaciclib (Primary) ; Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Jan 2019 Planned End Date changed from 31 Jan 2022 to 31 Mar 2022.
- 22 Jan 2019 Planned primary completion date changed from 31 Jan 2022 to 31 Mar 2022.
- 22 Jan 2019 Planned initiation date changed from 31 Dec 2018 to 28 Feb 2019.